69627-03-8

Basic information

• Product Name: 7-Chlorothieno[3,2-b]pyridine
• Synonyms: 7-Chlorothieno[3,2-b]pyridine;7-Chlorothieno[3,2-b]pyri...;7-chlorothieno[3;Thieno[3,2-b]pyridine, 7-chloro-
• CAS NO: 69627-03-8
• Molecular Formula: C₇H₄ClNS
• Molecular Weight: 169.63
• Product Categories: CHIRAL CHEMICALS;Thiophenes
• Mol File: 69627-03-8.mol
• Article Data: 26

Chemical Properties

• Melting Point: 34.0-35.5 °C
• Boiling Point: 257.5 °C at 760 mmHg
• Flash Point: 109.5 °C
• Appearance: /
• Density: 1.435 g/cm³
• Vapor Pressure: 0.0234mmHg at 25°C
• Refractive Index: 1.695
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.87±0.30(Predicted)
• CAS DataBase Reference: 7-Chlorothieno[3,2-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Chlorothieno[3,2-b]pyridine(69627-03-8)
• EPA Substance Registry System: 7-Chlorothieno[3,2-b]pyridine(69627-03-8)

Safety Data

• Hazardous Substances Data: 69627-03-8(Hazardous Substances Data)

Usage

General Description

7-Chlorothieno[3,2-b]pyridine is a chemical compound with the molecular formula C8H5ClNS. It is a heterocyclic compound that contains both sulfur and nitrogen atoms within its ring structure. 7-Chlorothieno[3,2-b]pyridine is widely used in the pharmaceutical industry as a building block for the synthesis of various pharmaceuticals and biologically active compounds. It is also known for its potential biological activities, particularly as an inhibitor of certain enzymes and as a potential anti-inflammatory agent. Additionally, this chemical has been studied for its potential use in the field of materials science, particularly in the development of organic semiconductor materials.

InChI:InChI=1/C7H4ClNS/c8-5-1-3-9-6-2-4-10-7(5)6/h1-4H

Upstream product

• 69627-02-7 thieno[3,2-b]pyridin-7(4H)-one 
• 34898-65-2 thieno<3,2-b>pyridine 4-oxide monohydrate 
• 69627-02-7 thieno[3,2-b]pyridin-7-ol 
• 79-37-8 oxalyl dichloride 
• 913377-45-4 2,2-dimethyl-5-{[(thiophen-3-yl)amino]methylidene}-1,3-dioxane-4,6-dione 
• 272-67-3 thieno[3,2-b]pyridine 
• 104273-28-1 7-nitrothieno<3,2-b>pyridine 4-oxide 
• 90691-08-0 4,7-dihydro-7-oxothieno<3,2-b>-7(4H)pyridine-6-carboxylic acid 
• 69626-98-8 6-ethoxycarbonylthieno<3,2-b>pyridin-7(4H)-one 
• 104273-29-2 7-chlorothieno<3,2-b>pyridine 4-oxide 

Downstream Products

• 272-67-3 thieno[3,2-b]pyridine 
• 871690-72-1 3-fluoro-4-(thieno[3,2-b]pyridin-7-yloxy)aniline 
• 387819-41-2 7-chlorothieno[3,2-b]pyridine-2-carbaldehyde 
• 225385-05-7 2-bromo-7-chlorothieno[3,2-b]pyridine 
• 638218-93-6 methyl 2-methyl-6-[thieno[3,2-b]pyridin-7-yloxy]benzofuran-3-carboxylate 
• 638219-78-0 2-methyl-6-(thieno[3,2-b]pyridin-7-yloxy)benzo[b]thiophene-3-carboxylic acid 
• 638217-57-9 7-chloro-2-(trimethylstannyl)thieno[3,2-b]pyridine 
• 875339-66-5 7-chloro-2-tributylstannanyl-thieno[3,2-b]pyridine 
• 875339-21-2 methyl 7-chlorothieno[3,2-b]pyridine-2-carboxylate 
• 918642-34-9 7-Chloro-2-(1-ethyl-1H-imidazol-5-yl)thieno[3,2-b]pyridine 
• 918642-37-2 7-Chloro-2-(1-isopropyl-1H-imidazol-4-yl)thieno[3,2-b]pyridine 
• 918642-40-7 7-Chloro-2-(1-propyl-1H-imidazol-4-yl)thieno[3,2-b]pyridine 
• 1228102-89-3 2-bromo-N-(3-(4-methoxybenzyloxy)phenyl)thieno[3,2-b]pyridin-7-amine 
• 1228102-90-6 4-(7-(3-(4-methoxybenzyloxy)phenylamino)thieno[3,2-b]pyridin-2-yl)benzaldehyde 

Relevant articles and documents

Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors

The synthesis and biological evaluation of novel 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 3, 4 and 5 as VEGFR-2 tyrosine kinase inhibitors, are reported. The 1-aryl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 4a-4h, with the arylurea in the meta position to the thioether, showed the lowest IC50 values in enzymatic assays (10-206 nM), the most potent compounds 4d-4h (IC50 10-28 nM) bearing hydrophobic groups (Me, F, CF3 and Cl) in the terminal phenyl ring. A convincing rationalization was achieved for the highest potent compounds 4 as type II VEGFR-2 inhibitors, based on the simultaneous presence of: (1) the thioether linker and (2) the arylurea moiety in the meta position. For compounds 4, significant inhibition of Human Umbilical Vein Endothelial Cells (HUVECs) proliferation (BrdU assay), migration (wound-healing assay) and tube formation were observed at low concentrations. These compounds have also shown to increase apoptosis using the TUNEL assay. Immunostaining for total and phosphorylated (active) VEGFR-2 was performed by Western blotting. The phosphorylation of the receptor was significantly inhibited at 1.0 and 2.5 μM for the most promising compounds. Altogether, these findings point to an antiangiogenic effect in HUVECs.

BIOMARKER-BASED THERAPEUTIC COMPOSITION

The present invention provides an anticancer agent for treating a patient who is resistant to a protein kinase inhibitor, the anticancer agent comprising, as an active ingredient, a thienopyridine derivative compound or a pharmaceutically acceptable salt thereof. Here, the patient may be a patient carrying active RON. In addition, the patient may be a patient carrying normal KRAS. In addition, the anticancer agent may be applied to a patient who is resistant to an EGFR inhibitor. In particular, the anticancer agent may be usefully used to treat a patient who is resistant to the therapeutic agent cetuximab.

Polysubstituted quinolone compounds, and preparation method and use thereof

The invention provides polysubstituted quinolone compounds, and a preparation method and a use thereof, and concretely provides a polysubstituted quinolone compound represented by formula I, and optical isomers, pharmaceutically acceptable salts or solvates thereof. All groups in the formula I are defined in the description. The quinolone compound has excellent c-Met inhibition activity, and can be used for treating c-Met activity or expression level corrected diseases.